Australia markets closed

ABBV Jan 2025 110.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.86000.0000 (0.00%)
As of 01:26PM EST. Market open.
Full screen
Previous close2.8600
Open2.8600
Bid0.0000
Ask0.0000
Strike110.00
Expiry date2025-01-17
Day's range2.8600 - 2.8600
Contract rangeN/A
Volume3
Open interest1.73k
  • Yahoo Finance Video

    FTC warns pharma companies on excessive drug patenting

    The Federal Trade Commission (FTC) issued warning letters to several pharmaceutical companies, including AbbVie (ABBV) AstraZeneca (AZN), and Teva (TEVA), over excessive patenting of medications as Medicare negotiates drug costs with the pharma industry. Yahoo Finance Health Reporter Anjalee Khemlani explains the Biden administration's ideas to license patents to lower drug costs for patients. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

  • Yahoo Finance Video

    AbbVie acquiring Cerevel Therapeutics in $8.7B deal

    AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal.  For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

  • Motley Fool

    3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows

    Buying these shares can provide you with some excellent recurring income while also diversifying your portfolio.